Common Contracts
8 similar Executive Employment Agreement contracts by X4 Pharmaceuticals, Inc
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 7, 2022, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Dr. Diego Cadavid (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 7, 2022, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Derek M. Meisner (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 7, 2022 (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Mary DiBiase, Ph.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 7, 2022, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Adam Mostafa (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 7, 2022, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Dr. Arthur Taveras (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of October 21, 2020, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Dr. Arthur Taveres (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of November 23, 2020, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Dr. Diego Cadavid (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 25, 2019, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Derek M. Meisner (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
